At the start of 2024, GSK is discontinuing Flovent, its popular branded asthma inhaler, and switching to a generic version. The generic is virtually identical, though physicians are worried that delays in securing insurance coverage will cause disruptions for patients, CNN reported Dec. 28.
Read the full post on Becker's Hospital Review - Healthcare News
